Rigel Pharmaceuticals traded at $48.18 this Friday September 4th, decreasing $0.32 or 0.66 percent since the previous trading session. Looking back, over the last four weeks, Rigel Pharmaceuticals lost 24.50 percent. Over the last 12 months, its price rose by 20.06 percent. Looking ahead, we forecast Rigel Pharmaceuticals to be priced at 45.49 by the end of this quarter and at 42.63 in one year, according to Trading Economics global macro models projections and analysts expectations.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.